Seres Therapeutics, Inc. has announced that its 2026 annual meeting of stockholders is set for June 9, 2026. All holders of record of common stock as of April 13, 2026, will be entitled to vote at the meeting. The specific time and location will be detailed in the definitive proxy statement for the meeting. This announcement is part of the company's compliance with SEC regulations, specifically under Rule 14a-5(f) of the Securities Exchange Act of 1934, which requires companies to provide notice of meetings that are scheduled more than 30 days after the anniversary of the previous year's meeting. Additionally, the company has set a deadline for stockholder proposals to be included in the proxy statement, which must be received by March 26, 2026. This proactive communication reflects Seres Therapeutics' commitment to transparency and shareholder engagement.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.